share_log

港股异动 | 同仁堂国药(03613)涨近6%领涨中医药概念 中医药发展政策有望持续出台 季度波动不改景气向上

Changes in Hong Kong stocks | Tong Ren Tang Sinopharm (03613) rose nearly 6%, leading the traditional Chinese medicine concept, the traditional Chinese medicine development policy is expected to continue to be introduced, quarterly fluctuations will not c

Zhitong Finance ·  Nov 21, 2023 01:43

Traditional Chinese medicine concept stocks generally rose today. As of press release, Kangchen Pharmaceutical (01681) rose 3.67% to HK$4.8; Tong Ren Tang Sinopharm (03613) rose 3.39% to HK$12.82; Baiyunshan (00874) rose 2.9% to HK$21.3; and Chinese Traditional Chinese Medicine (00570) rose 1.37% to HK$3.69.

The Zhitong Finance App learned that traditional Chinese medicine concept stocks were generally rising today. As of press release, Kangchen Pharmaceutical (01681) rose 3.67% to HK$4.8; Tong Ren Tang Sinopharm (03613) rose 3.39% to HK$12.82; Baiyunshan (00874) rose 2.9% to HK$21.3; and Chinese Traditional Chinese Medicine (00570) rose 1.37% to HK$3.69.

According to news, recently, the 2023 China Pharmaceutical Industry Development Conference was held. Wang Zhiyong, deputy director of the State Administration of Traditional Chinese Medicine, said that the next step is to further strengthen policy supply, increase protection, maintain the safety of traditional Chinese medicine development, effectively transform the resource advantages of traditional Chinese medicine into industrial advantages and competitive advantages, and add color to the high-quality development of the pharmaceutical industry through the iterative opening of the traditional Chinese medicine industry.

Zhongtai Securities said that in the third quarter, due to external factors in the industry, sales volume of in-hospital products was affected to a certain extent, but the upward trend in the Chinese medicine sector did not change. The current valuation of the Chinese medicine sector has a high cost performance ratio of configurations.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment